Form 4 for ADMA ADMA BIOLOGICS, INC.

Accepted 2022-12-09 00:00:00 ET · period of report 2022-12-09 · accession 0001140361-22-045111 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
	2022-12-09	2022-12-09	ADMA	Grossman Adam S	Pres, CEO, Dir	P - Purchase	$2.86	+15.0K	2.20M	+0.7%	+$42.9K
I	2022-12-09	2022-12-09	ADMA	Grossman Adam S	Pres, CEO, Dir	P - Purchase	$2.86	+15.0K	1.14M	+1%	+$42.8K

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2022-12-09	P	A	14,983	$2.86	2,203,708	D See Footnote	—	—	(F1) Represents a purchase from the underwriters in the December 2022 public offering of the issuer. (F4) (continued from prior footnote) (iv) 50,000 unvested RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (v) 783,315 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes. (F3) (continued from prior footnote) (iii) 162,893 unvested RSUs granted on February 25, 2021, of which 137,362 unvested RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 25,531 unvested RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting; (continued) (F2) Includes (i) 300,000 RSUs granted on March 7, 2022 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 907,500 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the "Time-Based RSUs"), of which (x) 50% of the Time Based RSUs shall vest on December 31, 2022 ("Initial Vesting Date") and (y) 50% of the Time-Based RSUs shall vest in eight (8) equal quarterly installments over a period of two years following the Initial Vesting Date, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date; (continued) (F5) These shares are owned by Areth, LLC ("Areth"). The reporting person is a control person of Areth.
2	Common	Common Stock	2022-12-09	P	A	14,982	$2.86	1,143,426	I	—	—	(F1) Represents a purchase from the underwriters in the December 2022 public offering of the issuer.